ipa-40fa_20210430.htm

British Columbia		8731		98-1508109
(Province or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number (if applicable))		(I.R.S. Employer Identification Number (if applicable))

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Shares, no par value

IPA

The NASDAQ Stock Market LLC

Securities registered or to be registered pursuant to Section 12(g) of the Act: None.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None.

For annual reports, indicate by check mark the information filed with this Form:

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: The Registrant had 19,169,216 Common Shares, no par value, issued and outstanding as of April 30, 2021

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

This Amendment No. 1 to Form 40-F (the “Form 40-F/A”) for the year ended April 30, 2021 is being filed to furnish the financial statements of ImmunoPrecise Antibodies Ltd. (the “Company”) for the fiscal year ended April 30, 2021 formatted in eXtensible Business Reporting Language (“XBRL”).

No other changes have been made to the Form 40-F other than the furnishing of the exhibit described above. This Amendment No. 1 does not reflect subsequent events occurring after the original date of the Form 40-F or modify or update in any way disclosures made in the Form 40-F.

Exhibit Number		Description

99.1*		Annual Information Form for the year ended April 30, 2021
99.2*		Audited Consolidated Financial Statements for the years ended April 30, 2021 and 2020 together with the notes thereto, including the report of the independent auditor thereon.
99.3*		Management’s Discussion and Analysis dated July 27, 2021, for the year ended April 30, 2021
99.4*		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14 of the Securities Exchange Act of 1934
99.5*		Certification of Chief Financial Officer required by Rules 13a-14(a) or 15d-14 of the Securities Exchange Act of 1934
99.6*		Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350
99.7*		Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350
99.8*		Consent of Crowe MacKay LLP
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused this annual report to be signed on its behalf by the undersigned, thereto duly authorized.

	IMMUNOPRECISE ANTIBODIES, LTD.

	By:		/s/ Jennifer Bath
	Name:		Jennifer Bath
	Title:		President and Chief Executive Officer